RT Journal Article
SR Electronic
T1 Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20085613
DO 10.1101/2020.04.30.20085613
A1 Wajnberg, Ania
A1 Mansour, Mayce
A1 Leven, Emily
A1 Bouvier, Nicole M.
A1 Patel, Gopi
A1 Firpo, Adolfo
A1 Mendu, Rao
A1 Jhang, Jeffrey
A1 Arinsburg, Suzanne
A1 Gitman, Melissa
A1 Houldsworth, Jane
A1 Baine, Ian
A1 Simon, Viviana
A1 Aberg, Judith
A1 Krammer, Florian
A1 Reich, David
A1 Cordon-Cardo, Carlos
YR 2020
UL http://medrxiv.org/content/early/2020/05/05/2020.04.30.20085613.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The percentage of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can still be detected at considerable time post symptom resolution. Here we investigated both seroconversion and PCR-positivity in a large cohort of convalescent serum donors in New York City.Methods Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via enzyme-linked immunosorbent assay for presence of anti SARS-CoV-2 spike antibodies.Results All but three confirmed SARS-CoV-2 patients seroconverted to the SARS-CoV-2 spike while only 37.4% of suspected SARS-CoV-2 patients seroconverted. PCR-positivity was detected up to 28 days from symptom resolution.Conclusions Here we show that the vast majority of confirmed COVID19 patients seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks post symptom resolution, but it is unclear if this signal represents infectious virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork on SARS-CoV-2 immunity in the Krammer is supported by the National Institute of Allergy and Infectious Disease (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 and the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C as well as institutional and philanthropic funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors are responsible for all data presented in the manuscript.